A half-day workshop at MD&M West will give attendees the chance to interact with both patients and new technologies. The session can help designers and engineers rapidly understand user needs and how empathy and co-creation can occur even within compressed schedules.
News & Features
The San Diego-based company presented at the 37th annual J.P. Morgan Healthcare Conference and said its revenue increased by 43% in 2018 despite mounting competition from rivals.
The Boulder, CO-based company has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.
CellMax Life has developed a blood test that it says can identify precancerous adenomas with similar accuracy as colonoscopy, which may facilitate better compliance with screenings and increase detection rates.
A team of researchers at the Imperial College London have developed a process known as known as traction force-activated payloads (TrAPs), that could have a significant impact on the body’s natural ability to heal.
The San Francisco-based company and developer of the Zio Patch is set to present at the 37th Annual J.P. Morgan Healthcare Conference this week.
A study from Mayo Clinic researchers shows less than two thirds of women ages 30 to 65 were up-to-date with cervical cancer screenings in 2016, which is below the 81% screening compliance rate self-reported in the 2015 National Health Interview Survey.
The New Year offers the chance to review your company’s marketing and sales practices given recent enforcement activity
The Irvine, CA-based company said it was limiting the device to only be available for use under clinical protocol with pre-screened patients that adhere to the current indications.
The Vetex Thrombectomy Catheter is designed to remove wall-to-wall clot within the vein, in one procedure, and without thrombolytic drugs.
Google’s former life sciences division said it would use the proceeds from the $1 billion investment round to help with its collaborations and potential acquisitions.
The company that developed the AngelMed implantable cardiac monitor system has filed for Chapter 11 bankruptcy.
Oculogica's concussion test takes some of the guesswork out of concussion assessment and does not require a baseline measurement for comparison.